bioMerieux released its Q3 17 trading results which were ahead of our estimates (revenue at CER: +9.6% vs AV’s estimate: +7.7%) on the back of strong growth momentum in the traditional microbiology business lines. While the clinical microbiology segment (+9.7% vs AV’s estimate: +4%; accounts for c.44% of Q3 17 sales) benefited from robust performance in the VITEK product line, growth in the industrial microbiology segment (+10.6% vs AV’s estimate: +4%; accounts for c.19% of
01 Nov 2017
Another strong quarter but Q4 likely to be slower in comparison
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Another strong quarter but Q4 likely to be slower in comparison
bioMerieux released its Q3 17 trading results which were ahead of our estimates (revenue at CER: +9.6% vs AV’s estimate: +7.7%) on the back of strong growth momentum in the traditional microbiology business lines. While the clinical microbiology segment (+9.7% vs AV’s estimate: +4%; accounts for c.44% of Q3 17 sales) benefited from robust performance in the VITEK product line, growth in the industrial microbiology segment (+10.6% vs AV’s estimate: +4%; accounts for c.19% of